Comparative Pharmacology
Head-to-head clinical analysis: APIDRA versus NOVOLIN 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA versus NOVOLIN 70 30.
APIDRA vs NOVOLIN 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a rapid-acting insulin analog that lowers blood glucose by binding to and activating insulin receptors on cells, facilitating glucose uptake into muscle and adipose tissue, and inhibiting hepatic glucose production.
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
Subcutaneous injection 0.2-0.4 units/kg once daily or divided twice daily, or as part of basal-bolus regimen with 50-70% of total daily insulin as prandial insulin given within 15 minutes before or within 20 minutes after starting a meal.
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
None Documented
None Documented
Terminal elimination half-life is approximately 30 minutes. This short half-life allows for flexible dosing and rapid clearance, but necessitates multiple daily injections or continuous subcutaneous insulin infusion.
Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours.
Primarily renal; ~60% of a dose is excreted as metabolites and unchanged drug in urine. Fecal elimination is minimal (<10%).
Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible.
Category C
Category C
Insulin
Insulin